BioMedPartners

BioMedPartners is a specialized Swiss healthcare investor based in Basel, focused heavily on biopharmaceuticals and diagnostics stemming from the DACH region. The firm sits at the heart of the Basel pharma cluster and leverages those networks to source and support biotech, pharma/therapeutics, and medical device companies with strong scientific foundations. Their core thesis blends German, Swiss, and Austrian academic and industrial science into a clinically credible early-stage portfolio.

BioMedPartners invests across Seed, Series A, and Series B, with checks of $1M to $5M, often participating in syndicates alongside larger European and US specialist healthcare funds. Geographic focus is firmly DACH-led, with selective European deployment where the science aligns and a willingness to follow portfolio companies into US-led later rounds.

Founders should expect deep scientific diligence informed by Basel’s pharma operator network, with particular attention to therapeutic mechanism, IP defensibility, and clinical development plan. Limited public information is available on the full portfolio, so warm introductions through DACH life sciences advisors, KOLs, or co-investors are the most effective entry. A clear syndication path including transatlantic later-stage capital strengthens the case.